Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAILBLAZER-ALZ 2
NCT04437511Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2020
- Primary completion
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of donanemab in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Jun 2020; status: active, not recruiting.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04437511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04437511.